mTOR, cardiomyocytes and inflammation in cardiac hypertrophy

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1863, Issue 7, 2016, Pages 1894-1903

  Xu, Lifen ^a   Brink, Marijke ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Cardiomyocyte; Inflammation; mTOR; NF kappaB; Protein degradation; Protein synthesis

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; RAPAMYCIN; AUTACOID; CARDIOVASCULAR AGENT; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

CARDIAC MUSCLE CELL; ENZYME INACTIVATION; GENE OVEREXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC STRESS; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; TISSUE SPECIFICITY; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOMEGALY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEART VENTRICLE REMODELING; METABOLISM; MYOCARDITIS; PATHOLOGY; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMEGALY; CARDIOVASCULAR AGENTS; HUMANS; INFLAMMATION MEDIATORS; MYOCARDITIS; MYOCYTES, CARDIAC; PROTEIN BIOSYNTHESIS; PROTEIN KINASE INHIBITORS; PROTEOLYSIS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VENTRICULAR REMODELING;

EID: 84957922925     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2016.01.003     Document Type: Review

References (148)

1. Albert V., Hall M.N. MTOR signaling in cellular and organismal energetics. Curr. Opin. Cell Biol. 2015, 33:55-66.
2. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
3. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
4. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 2009, 10:307-318.
5. Iadevaia V., Huo Y., Zhang Z., Foster L.J., Proud C.G. Roles of the mammalian target of rapamycin, mTOR, in controlling ribosome biogenesis and protein synthesis. Biochem. Soc. Trans. 2012, 40:168-172.
6. Mieulet V., Roceri M., Espeillac C., Sotiropoulos A., Ohanna M., Oorschot V., Klumperman J., Sandri M., Pende M. S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover. Am. J. Physiol. Cell Physiol. 2007, 293:C712-C722.
7. Chauvin C., Koka V., Nouschi A., Mieulet V., Hoareau-Aveilla C., Dreazen A., Cagnard N., Carpentier W., Kiss T., Meyuhas O., Pende M. Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene 2014, 33:474-483.
8. Hsieh A.C., Liu Y., Edlind M.P., Ingolia N.T., Janes M.R., Sher A., Shi E.Y., Stumpf C.R., Christensen C., Bonham M.J., Wang S., Ren P., Martin M., Jessen K., Feldman M.E., Weissman J.S., Shokat K.M., Rommel C., Ruggero D. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012, 485:55-61.
9. Thoreen C.C., Chantranupong L., Keys H.R., Wang T., Gray N.S., Sabatini D.M. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012, 485:109-113.
10. McMullen J.R., Shioi T., Zhang L., Tarnavski O., Sherwood M.C., Dorfman A.L., Longnus S., Pende M., Martin K.A., Blenis J., Thomas G., Izumo S. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol. Cell. Biol. 2004, 24:6231-6240.
11. Shioi T., Kang P.M., Douglas P.S., Hampe J., Yballe C.M., Lawitts J., Cantley L.C., Izumo S. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 2000, 19:2537-2548.
12. Meyuhas O., Kahan T. The race to decipher the top secrets of TOP mRNAs. Biochim. Biophys. Acta 2015, 1849:801-811.
13. Larsson O., Morita M., Topisirovic I., Alain T., Blouin M.J., Pollak M., Sonenberg N. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:8977-8982.
14. Morita M., Gravel S.P., Chenard V., Sikstrom K., Zheng L., Alain T., Gandin V., Avizonis D., Arguello M., Zakaria C., McLaughlan S., Nouet Y., Pause A., Pollak M., Gottlieb E., Larsson O., St-Pierre J., Topisirovic I., Sonenberg N. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 2013, 18:698-711.
15. Tsai S., Sitzmann J.M., Dastidar S.G., Rodriguez A.A., Vu S.L., McDonald C.E., Academia E.C., O'Leary M.N., Ashe T.D., La Spada A.R., Kennedy B.K. Muscle-specific 4E-BP1 signaling activation improves metabolic parameters during aging and obesity. J. Clin. Invest. 2015, 125:2952-2964.
16. Robida-Stubbs S., Glover-Cutter K., Lamming D.W., Mizunuma M., Narasimhan S.D., Neumann-Haefelin E., Sabatini D.M., Blackwell T.K. TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. Cell Metab. 2012, 15:713-724.
17. Zid B.M., Rogers A.N., Katewa S.D., Vargas M.A., Kolipinski M.C., Lu T.A., Benzer S., Kapahi P. 4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in Drosophila. Cell 2009, 139:149-160.
18. Rogers A.N., Chen D., McColl G., Czerwieniec G., Felkey K., Gibson B.W., Hubbard A., Melov S., Lithgow G.J., Kapahi P. Life span extension via eIF4G inhibition is mediated by posttranscriptional remodeling of stress response gene expression in C. elegans. Cell Metab. 2011, 14:55-66.
19. Cornu M., Albert V., Hall M.N. mTOR in aging, metabolism, and cancer. Curr. Opin. Genet. Dev. 2013, 23:53-62.
20. Shende P., Xu L., Morandi C., Pentassuglia L., Heim P., Lebboukh S., Berthonneche C., Pedrazzini T., Kaufmann B.A., Hall M.N., Ruegg M.A., Brink M. Cardiac mTOR complex 2 preserves ventricular function in pressure-overload hypertrophy. Cardiovasc. Res. 2015.
21. Russell R.C., Yuan H.X., Guan K.L. Autophagy regulation by nutrient signaling. Cell Res. 2014, 24:42-57.
22. Gatica D., Chiong M., Lavandero S., Klionsky D.J. Molecular mechanisms of autophagy in the cardiovascular system. Circ. Res. 2015, 116:456-467.
23. Gottlieb R.A., Andres A.M., Sin J., Taylor D.P. Untangling autophagy measurements: all fluxed up. Circ. Res. 2015, 116:504-514.
24. Jimenez R.E., Kubli D.A., Gustafsson A.B. Autophagy and mitophagy in the myocardium: therapeutic potential and concerns. Br. J. Pharmacol. 2014, 171:1907-1916.
25. Ren S.Y., Xu X. Role of autophagy in metabolic syndrome-associated heart disease. Biochim. Biophys. Acta 2014.
26. Rifki O.F., Hill J.A. Cardiac autophagy: good with the bad. J. Cardiovasc. Pharmacol. 2012, 60:248-252.
27. Saito T., Sadoshima J. Molecular mechanisms of mitochondrial autophagy/mitophagy in the heart. Circ. Res. 2015, 116:1477-1490.
28. Wang Z.V., Ferdous A., Hill J.A. Cardiomyocyte autophagy: metabolic profit and loss. Heart Fail. Rev. 2012.
29. Zhang Y., Nicholatos J., Dreier J.R., Ricoult S.J., Widenmaier S.B., Hotamisligil G.S., Kwiatkowski D.J., Manning B.D. Coordinated regulation of protein synthesis and degradation by mTORC1. Nature 2014, 513:440-443.
30. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Exp. Biol. Med. 2006, 231:1197-1211.
31. Wang X., Robbins J. Heart failure and protein quality control. Circ. Res. 2006, 99:1315-1328.
32. Schlossarek S., Carrier L. The ubiquitin-proteasome system in cardiomyopathies. Curr. Opin. Cardiol. 2011, 26:190-195.
33. Portbury A.L., Willis M.S., Patterson C. Tearin' up my heart: proteolysis in the cardiac sarcomere. J. Biol. Chem. 2011, 286:9929-9934.
34. Willis M.S., Bevilacqua A., Pulinilkunnil T., Kienesberger P., Tannu M., Patterson C. The role of ubiquitin ligases in cardiac disease. J. Mol. Cell. Cardiol. 2014, 71:43-53.
35. Wang Z.V., Hill J.A. Protein quality control and metabolism: bidirectional control in the heart. Cell Metab. 2015, 21:215-226.
36. Portbury A.L., Ronnebaum S.M., Zungu M., Patterson C., Willis M.S. Back to your heart: ubiquitin proteasome system-regulated signal transduction. J. Mol. Cell. Cardiol. 2012, 52:526-537.
37. Powell S.R., Herrmann J., Lerman A., Patterson C., Wang X. The ubiquitin-proteasome system and cardiovascular disease. Prog. Mol. Biol. Transl. Sci. 2012, 109:295-346.
38. Dai D.F., Karunadharma P.P., Chiao Y.A., Basisty N., Crispin D., Hsieh E.J., Chen T., Gu H., Djukovic D., Raftery D., Beyer R.P., MacCoss M.J., Rabinovitch P.S. Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. Aging Cell 2014, 13:529-539.
39. Ikenoue T., Inoki K., Yang Q., Zhou X., Guan K.L. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 2008, 27:1919-1931.
40. Facchinetti V., Ouyang W., Wei H., Soto N., Lazorchak A., Gould C., Lowry C., Newton A.C., Mao Y., Miao R.Q., Sessa W.C., Qin J., Zhang P., Su B., Jacinto E. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 2008, 27:1932-1943.
41. Yang H., Rudge D.G., Koos J.D., Vaidialingam B., Yang H.J., Pavletich N.P. MTOR kinase structure, mechanism and regulation. Nature 2013, 497:217-223.
42. Aylett C.H., Sauer E., Imseng S., Boehringer D., Hall M.N., Ban N., Maier T. Architecture of human mTOR complex 1. Science 2015.
43. Thoreen C.C., Sabatini D.M. Rapamycin inhibits mTORC1, but not completely. Autophagy 2009, 5:725-726.
44. Kang S.A., Pacold M.E., Cervantes C.L., Lim D., Lou H.J., Ottina K., Gray N.S., Turk B.E., Yaffe M.B., Sabatini D.M. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 2013, 341:1236566.
45. Shimobayashi M., Hall M.N. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat. Rev. Mol. Cell Biol. 2014, 15:155-162.
46. Harston R.K., McKillop J.C., Moschella P.C., Van Laer A., Quinones L.S., Baicu C.F., Balasubramanian S., Zile M.R., Kuppuswamy D. Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H1696-H1706.
47. Zhang H.M., Fu J., Hamilton R., Diaz V., Zhang Y. The mammalian target of rapamycin modulates the immunoproteasome system in the heart. J. Mol. Cell. Cardiol. 2015, 86:158-167.
48. Ackermann M.A. Links between mTOR and the immunoproteasome: therapeutic targets for cardiac hypertrophy?. J. Mol. Cell. Cardiol. 2015.
49. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 1990, 323:236-241.
50. Mann D.L. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ. Res. 2015, 116:1254-1268.
51. Li Y., Ha T., Gao X., Kelley J., Williams D.L., Browder I.W., Kao R.L., Li C. NF-kappaB activation is required for the development of cardiac hypertrophy in vivo. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H1712-H1720.
52. Ha T., Li Y., Gao X., McMullen J.R., Shioi T., Izumo S., Kelley J.L., Zhao A., Haddad G.E., Williams D.L., Browder I.W., Kao R.L., Li C. Attenuation of cardiac hypertrophy by inhibiting both mTOR and NFkappaB activation in vivo. Free Radic. Biol. Med. 2005, 39:1570-1580.
53. Kashiwase K., Higuchi Y., Hirotani S., Yamaguchi O., Hikoso S., Takeda T., Watanabe T., Taniike M., Nakai A., Tsujimoto I., Matsumura Y., Ueno H., Nishida K., Hori M., Otsu K. CaMKII activates ASK1 and NF-kappaB to induce cardiomyocyte hypertrophy. Biochem. Biophys. Res. Commun. 2005, 327:136-142.
54. Vellaichamy E., Sommana N.K., Pandey K.N. Reduced cGMP signaling activates NF-kappaB in hypertrophied hearts of mice lacking natriuretic peptide receptor-a. Biochem. Biophys. Res. Commun. 2005, 327:106-111.
55. Gordon J.W., Shaw J.A., Kirshenbaum L.A. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ. Res. 2011, 108:1122-1132.
56. Liang F., Gardner D.G. Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism. J. Clin. Invest. 1999, 104:1603-1612.
57. Purcell N.H., Yu C., He D., Xiang J., Paran N., DiDonato J.A., Yamaoka S., Shaul Y., Lin A. Activation of NF-kappaB by hepatitis B virus X protein through an IkappaB kinase-independent mechanism. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 280:G669-G677.
58. Purcell N.H., Molkentin J.D. Is nuclear factor kappaB an attractive therapeutic target for treating cardiac hypertrophy?. Circulation 2003, 108:638-640.
59. Hirotani S., Otsu K., Nishida K., Higuchi Y., Morita T., Nakayama H., Yamaguchi O., Mano T., Matsumura Y., Ueno H., Tada M., Hori M. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002, 105:509-515.
60. Freund C., Schmidt-Ullrich R., Baurand A., Dunger S., Schneider W., Loser P., El-Jamali A., Dietz R., Scheidereit C., Bergmann M.W. Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005, 111:2319-2325.
61. Zelarayan L., Renger A., Noack C., Zafiriou M.P., Gehrke C., van der Nagel R., Dietz R., de Windt L., Bergmann M.W. NF-kappaB activation is required for adaptive cardiac hypertrophy. Cardiovasc. Res. 2009, 84:416-424.
62. Karin M., Yamamoto Y., Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 2004, 3:17-26.
63. Ock S., Ahn J., Lee S.H., Park H., Son J.W., Oh J.G., Yang D.K., Lee W.S., Kim H.S., Rho J., Oh G.T., Abel E.D., Park W.J., Min J.K., Kim J. Receptor activator of nuclear factor-kappaB ligand is a novel inducer of myocardial inflammation. Cardiovasc. Res. 2012, 94:105-114.
64. Chen X., Zeng S., Zou J., Chen Y., Yue Z., Gao Y., Zhang L., Cao W., Liu P. Rapamycin attenuated cardiac hypertrophy induced by isoproterenol and maintained energy homeostasis via inhibiting NF-kappaB activation. Mediat. Inflamm. 2014, 2014:868753.
65. Kamo T., Akazawa H., Komuro I. Cardiac nonmyocytes in the hub of cardiac hypertrophy. Circ. Res. 2015, 117:89-98.
66. Kakkar R., Lee R.T. Intramyocardial fibroblast myocyte communication. Circ. Res. 2010, 106:47-57.
67. Aoyagi T., Matsui T. The cardiomyocyte as a source of cytokines in cardiac injury. J. Cell Sci. Ther. 2012, 2011.
68. Xia Y., Lee K., Li N., Corbett D., Mendoza L., Frangogiannis N.G. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem. Cell Biol. 2009, 131:471-481.
69. Weisheit C., Zhang Y., Faron A., Kopke O., Weisheit G., Steinstrasser A., Frede S., Meyer R., Boehm O., Hoeft A., Kurts C., Baumgarten G. Ly6C(low) and not Ly6C(high) macrophages accumulate first in the heart in a model of murine pressure-overload. PLoS One 2014, 9.
70. Ghigo A., Franco I., Morello F., Hirsch E. Myocyte signalling in leucocyte recruitment to the heart. Cardiovasc. Res. 2014, 102:270-280.
71. Nevers T., Salvador A.M., Grodecki-Pena A., Knapp A., Velazquez F., Aronovitz M., Kapur N.K., Karas R.H., Blanton R.M., Alcaide P. Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure, Circulation. Heart Fail. 2015, 8:776-787.
72. Wang C., Qin L., Manes T.D., Kirkiles-Smith N.C., Tellides G., Pober J.S. Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2. J. Exp. Med. 2014, 211:395-404.
73. Shioi T., McMullen J.R., Kang P.M., Douglas P.S., Obata T., Franke T.F., Cantley L.C., Izumo S. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 2002, 22:2799-2809.
74. Bishu K., Ogut O., Kushwaha S., Mohammed S.F., Ohtani T., Xu X., Brozovich F.V., Redfield M.M. Anti-remodeling effects of rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockade. PLoS One 2013, 8.
75. Shen W.H., Chen Z., Shi S., Chen H., Zhu W., Penner A., Bu G., Li W., Boyle D.W., Rubart M., Field L.J., Abraham R., Liechty E.A., Shou W. Cardiac restricted overexpression of kinase-dead mammalian target of rapamycin (mTOR) mutant impairs the mTOR-mediated signaling and cardiac function. J. Biol. Chem. 2008, 283:13842-13849.
76. Zhu Y., Pires K.M., Whitehead K.J., Olsen C.D., Wayment B., Zhang Y.C., Bugger H., Ilkun O., Litwin S.E., Thomas G., Kozma S.C., Abel E.D. Mechanistic target of rapamycin (mTOR) is essential for murine embryonic heart development and growth. PLoS One 2013, 8.
77. Zhang D., Contu R., Latronico M.V., Zhang J.L., Rizzi R., Catalucci D., Miyamoto S., Huang K., Ceci M., Gu Y., Dalton N.D., Peterson K.L., Guan K.L., Brown J.H., Chen J., Sonenberg N., Condorelli G. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J. Clin. Invest. 2010, 120:2805-2816.
78. Shende P., Plaisance I., Morandi C., Pellieux C., Berthonneche C., Zorzato F., Krishnan J., Lerch R., Hall M.N., Ruegg M.A., Pedrazzini T., Brink M. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation 2011, 123:1073-1082.
79. Wu X., Cao Y., Nie J., Liu H., Lu S., Hu X., Zhu J., Zhao X., Chen J., Chen X., Yang Z., Li X. Genetic and pharmacological inhibition of Rheb1-mTORC1 signaling exerts cardioprotection against adverse cardiac remodeling in mice. Am. J. Pathol. 2013, 182:2005-2014.
80. Volkers M., Toko H., Doroudgar S., Din S., Quijada P., Joyo A.Y., Ornelas L., Joyo E., Thuerauf D.J., Konstandin M.H., Gude N., Glembotski C.C., Sussman M.A. Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:12661-12666.
81. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., Brown M., Fitzgerald K.J., Sabatini D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 2006, 11:859-871.
82. Shiota C., Woo J.T., Lindner J., Shelton K.D., Magnuson M.A. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell 2006, 11:583-589.
83. Yang Q., Inoki K., Ikenoue T., Guan K.L. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 2006, 20:2820-2832.
84. Lamming D.W., Mihaylova M.M., Katajisto P., Baar E.L., Yilmaz O.H., Hutchins A., Gultekin Y., Gaither R., Sabatini D.M. Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan. Aging Cell 2014.
85. Volkers M., Konstandin M.H., Doroudgar S., Toko H., Quijada P., Din S., Joyo A., Ornelas L., Samse K., Thuerauf D.J., Gude N., Glembotski C.C., Sussman M.A. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage. Circulation 2013, 128:2132-2144.
86. Yano T., Ferlito M., Aponte A., Kuno A., Miura T., Murphy E., Steenbergen C. Pivotal role of mTORC2 and involvement of ribosomal protein S6 in cardioprotective signaling. Circ. Res. 2014, 114:1268-1280.
87. Sciarretta S., Zhai P., Maejima Y., Del Re D.P., Nagarajan N., Yee D., Liu T., Magnuson M.A., Volpe M., Frati G., Li H., Sadoshima J. mTORC2 regulates cardiac response to stress by inhibiting MST1. Cell Rep. 2015, 11:125-136.
88. Sadoshima J., Izumo S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ. Res. 1995, 77:1040-1052.
89. Boluyt M.O., Zheng J.S., Younes A., Long X., O'Neill L., Silverman H., Lakatta E.G., Crow M.T. Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase. Circ. Res. 1997, 81:176-186.
90. Wang L., Proud C.G. Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes. Circ. Res. 2002, 91:821-829.
91. Simm A., Schluter K., Diez C., Piper H.M., Hoppe J. Activation of p70(S6) kinase by beta-adrenoceptor agonists on adult cardiomyocytes. J. Mol. Cell. Cardiol. 1998, 30:2059-2067.
92. Wang L., Gout I., Proud C.G. Cross-talk between the ERK and p70 S6 kinase (S6K) signaling pathways. MEK-dependent activation of S6K2 in cardiomyocytes. J. Biol. Chem. 2001, 276:32670-32677.
93. Rolfe M., McLeod L.E., Pratt P.F., Proud C.G. Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). Biochem. J. 2005, 388:973-984.
94. Wang L., Rolfe M., Proud C.G. Ca(2+)-independent protein kinase C activity is required for alpha1-adrenergic-receptor-mediated regulation of ribosomal protein S6 kinases in adult cardiomyocytes. Biochem. J. 2003, 373:603-611.
95. Iijima Y., Laser M., Shiraishi H., Willey C.D., Sundaravadivel B., Xu L., McDermott P.J., Kuppuswamy D. c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J. Biol. Chem. 2002, 277:23065-23075.
96. Moschella P.C., Rao V.U., McDermott P.J., Kuppuswamy D. Regulation of mTOR and S6K1 activation by the nPKC isoforms, PKCepsilon and PKCdelta, in adult cardiac muscle cells. J. Mol. Cell. Cardiol. 2007, 43:754-766.
97. Shiojima I., Walsh K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev. 2006, 20:3347-3365.
98. Shioi T., McMullen J.R., Tarnavski O., Converso K., Sherwood M.C., Manning W.J., Izumo S. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003, 107:1664-1670.
99. McMullen J.R., Sherwood M.C., Tarnavski O., Zhang L., Dorfman A.L., Shioi T., Izumo S. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004, 109:3050-3055.
100. Krenz M., Robbins J. Impact of beta-myosin heavy chain expression on cardiac function during stress. J. Am. Coll. Cardiol. 2004, 44:2390-2397.
101. Periasamy M. Adenoviral-mediated serca gene transfer into cardiac myocytes: how much is too much?. Circ. Res. 2001, 88:373-375.
102. Periasamy M., Huke S. SERCA pump level is a critical determinant of Ca(2+)homeostasis and cardiac contractility. J. Mol. Cell. Cardiol. 2001, 33:1053-1063.
103. Nakayama H., Otsu K., Yamaguchi O., Nishida K., Date M.O., Hongo K., Kusakari Y., Toyofuku T., Hikoso S., Kashiwase K., Takeda T., Matsumura Y., Kurihara S., Hori M., Tada M. Cardiac-specific overexpression of a high Ca2+ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 2003, 17:61-63.
104. Creemers E.E., Pinto Y.M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc. Res. 2011, 89:265-272.
105. Gao X.M., Wong G., Wang B., Kiriazis H., Moore X.L., Su Y.D., Dart A., Du X.J. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J. Hypertens. 2006, 24:1663-1670.
106. Aoyagi T., Kusakari Y., Xiao C.Y., Inouye B.T., Takahashi M., Scherrer-Crosbie M., Rosenzweig A., Hara K., Matsui T. Cardiac mTOR protects the heart against ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2012, 303:H75-H85.
107. Siedlecki A.M., Jin X., Muslin A.J. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int. 2009, 75:800-808.
108. Shiojima I., Sato K., Izumiya Y., Schiekofer S., Ito M., Liao R., Colucci W.S., Walsh K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 2005, 115:2108-2118.
109. Davis J., Molkentin J.D. Myofibroblasts: trust your heart and let fate decide. J. Mol. Cell. Cardiol. 2014, 70:9-18.
110. Goldsmith E.C., Bradshaw A.D., Zile M.R., Spinale F.G. Myocardial fibroblast-matrix interactions and potential therapeutic targets. J. Mol. Cell. Cardiol. 2014, 70:92-99.
111. Schroer A.K., Merryman W.D. Mechanobiology of myofibroblast adhesion in fibrotic cardiac disease. J. Cell Sci. 2015, 128:1865-1875.
112. Rienks M., Papageorgiou A.P., Frangogiannis N.G., Heymans S. Myocardial extracellular matrix: an ever-changing and diverse entity. Circ. Res. 2014, 114:872-888.
113. Freed D.H., Borowiec A.M., Angelovska T., Dixon I.M. Induction of protein synthesis in cardiac fibroblasts by cardiotrophin-1: integration of multiple signaling pathways. Cardiovasc. Res. 2003, 60:365-375.
114. Ha T., Li Y., Hua F., Ma J., Gao X., Kelley J., Zhao A., Haddad G.E., Williams D.L., William Browder I., Kao R.L., Li C. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc. Res. 2005, 68:224-234.
115. R G.H.D., Y W., AK B., Y A., V M., A T., LA K. Bidirectional regulation of nuclear factor-kB and mammalian target of rapamycin signaling functionally links Bnip3 gene repression and cell survival of ventricular myocytes, Circulation. Heart Fail. 2013, 6:335.
116. Zhao Q.D., Viswanadhapalli S., Williams P., Shi Q., Tan C., Yi X., Bhandari B., Abboud H.E. NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFkappaB signaling pathways. Circulation 2015, 131:643-655.
117. Song X., Kusakari Y., Xiao C.Y., Kinsella S.D., Rosenberg M.A., Scherrer-Crosbie M., Hara K., Rosenzweig A., Matsui T. MTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy. Am. J. Physiol. Cell Physiol. 2010, 299:C1256-C1266.
118. Molkentin J.D., Robbins J. With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure. J. Mol. Cell. Cardiol. 2009, 46:130-136.
119. Soesanto W., Lin H.Y., Hu E., Lefler S., Litwin S.E., Sena S., Abel E.D., Symons J.D., Jalili T. Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 2009, 54:1321-1327.
120. Marin T.M., Keith K., Davies B., Conner D.A., Guha P., Kalaitzidis D., Wu X., Lauriol J., Wang B., Bauer M., Bronson R., Franchini K.G., Neel B.G., Kontaridis M.I. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J. Clin. Invest. 2011, 121:1026-1043.
121. Kuzman J.A., O'Connell T.D., Gerdes A.M. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy. Endocrinology 2007, 148:3477-3484.
122. Buss S.J., Muenz S., Riffel J.H., Malekar P., Hagenmueller M., Weiss C.S., Bea F., Bekeredjian R., Schinke-Braun M., Izumo S., Katus H.A., Hardt S.E. Beneficial effects of mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. J. Am. Coll. Cardiol. 2009, 54:2435-2446.
123. Xu X., Roe N.D., Weiser-Evans M.C., Ren J. Inhibition of mammalian target of rapamycin with rapamycin reverses hypertrophic cardiomyopathy in mice with cardiomyocyte-specific knockout of PTEN. Hypertension 2014, 63:729-739.
124. Schramm C., Fine D.M., Edwards M.A., Reeb A.N., Krenz M. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling. Am. J. Physiol. Heart Circ. Physiol. 2012, 302:H231-H243.
125. Clemente C.F., Xavier-Neto J., Dalla Costa A.P., Consonni S.R., Antunes J.E., Rocco S.A., Pereira M.B., Judice C.C., Strauss B., Joazeiro P.P., Matos-Souza J.R., Franchini K.G. Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways. J. Mol. Cell. Cardiol. 2012, 52:493-501.
126. Franchini K.G. Focal adhesion kinase-the basis of local hypertrophic signaling domains. J. Mol. Cell. Cardiol. 2012, 52:485-492.
127. Drolet M.C., Desbiens-Brassard V., Roussel E., Tu V., Couet J., Arsenault M. Blockade of the acute activation of mTOR complex 1 decreases hypertrophy development in rats with severe aortic valve regurgitation. SpringerPlus 2015, 4:435.
128. Flynn J.M., O'Leary M.N., Zambataro C.A., Academia E.C., Presley M.P., Garrett B.J., Zykovich A., Mooney S.D., Strong R., Rosen C.J., Kapahi P., Nelson M.D., Kennedy B.K., Melov S. Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell 2013, 12:851-862.
129. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168.
130. Lamming D.W., Ye L., Katajisto P., Goncalves M.D., Saitoh M., Stevens D.M., Davis J.G., Salmon A.B., Richardson A., Ahima R.S., Guertin D.A., Sabatini D.M., Baur J.A. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012, 335:1638-1643.
131. Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N.R., Cheng S., Shepherd P.R., Gout I., Downes C.P., Lamb R.F. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 2004, 166:213-223.
132. Um S.H., Frigerio F., Watanabe M., Picard F., Joaquin M., Sticker M., Fumagalli S., Allegrini P.R., Kozma S.C., Auwerx J., Thomas G. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004, 431:200-205.
133. Shah O.J., Wang Z., Hunter T. Inappropriate activation of the TSC/rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol.: CB 2004, 14:1650-1656.
134. Yu Y., Yoon S.O., Poulogiannis G., Yang Q., Ma X.M., Villen J., Kubica N., Hoffman G.R., Cantley L.C., Gygi S.P., Blenis J. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011, 332:1322-1326.
135. Hsu P.P., Kang S.A., Rameseder J., Zhang Y., Ottina K.A., Lim D., Peterson T.R., Choi Y., Gray N.S., Yaffe M.B., Marto J.A., Sabatini D.M. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011, 332:1317-1322.
136. Zhang D., Contu R., Latronico M.V., Zhang J., Rizzi R., Catalucci D., Miyamoto S., Huang K., Ceci M., Gu Y., Dalton N.D., Peterson K.L., Guan K.L., Brown J.H., Chen J., Sonenberg N., Condorelli G. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J. Clin. Invest. 2010, 120:2805-2816.
137. Schreiber K.H., Ortiz D., Academia E.C., Anies A.C., Liao C.Y., Kennedy B.K. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. Aging Cell 2015, 14:265-273.
138. Takeda I.M.N. Cellular interplay between cardiomyocytes and nonmyocytes in cardiac remodeling. Int. J. Inflamm. 2011, 2011.
139. Yndestad A., Damas J.K., Oie E., Ueland T., Gullestad L., Aukrust P. Role of inflammation in the progression of heart failure. Curr. Cardiol. Rep. 2007, 9:236-241.
140. Ueland T., Gullestad L., Nymo S.H., Yndestad A., Aukrust P., Askevold E.T. Inflammatory cytokines as biomarkers in heart failure. Clin. Chim. Acta 2015, 443:71-77.
141. Askevold E.T., Gullestad L., Dahl C.P., Yndestad A., Ueland T., Aukrust P. Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. Curr. Heart Fail. Rep. 2014, 11:146-155.
142. Hua Y., Zhang Y., Ceylan-Isik A.F., Wold L.E., Nunn J.M., Ren J. Chronic Akt activation accentuates aging-induced cardiac hypertrophy and myocardial contractile dysfunction: role of autophagy. Basic Res. Cardiol. 2011, 106:1173-1191.
143. Neff F., Flores-Dominguez D., Ryan D.P., Horsch M., Schroder S., Adler T., Afonso L.C., Aguilar-Pimentel J.A., Becker L., Garrett L., Hans W., Hettich M.M., Holtmeier R., Holter S.M., Moreth K., Prehn C., Puk O., Racz I., Rathkolb B., Rozman J., Naton B., Ordemann R., Adamski J., Beckers J., Bekeredjian R., Busch D.H., Ehninger G., Graw J., Hofler H., Klingenspor M., Klopstock T., Ollert M., Stypmann J., Wolf E., Wurst W., Zimmer A., Fuchs H., Gailus-Durner V., Angelis M.H.d., Ehninger D. Rapamycin extends murine lifespan but has limited effects on aging. J. Clin. Invest. 2013, 123:3272-3291.
144. Weichhart T. Mammalian target of rapamycin: a signaling kinase for every aspect of cellular life. Methods Mol. Biol. 2012, 821:1-14.
145. Weichhart T., Hengstschlager M., Linke M. Regulation of innate immune cell function by mTOR. Nat. Rev. Immunol. 2015, 15:599-614.
146. Weichhart T., Saemann M.D. The multiple facets of mTOR in immunity. Trends Immunol. 2009, 30:218-226.
147. Soliman G.A. The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses. Nutrients 2013, 5:2231-2257.
148. Saleiro D., Platanias L.C. Intersection of mTOR and STAT signaling in immunity. Trends Immunol. 2015, 36:21-29.